Last reviewed · How we verify
Velcade
Velcade is a Small molecule drug developed by University of Arkansas. It is currently FDA-approved for Mantle cell lymphoma, Multiple myeloma, Systemic AL amyloidosis. Also known as: Bortezomib, PS-341, Bendamustine HCl, Treanda.
Velcade, also known as Bortezomib, is an anti-cancer medication used to treat multiple myeloma, including cases that have and have not previously received treatment. It is typically administered by injection and is often used in combination with other medications.
At a glance
| Generic name | Velcade |
|---|---|
| Also known as | Bortezomib, PS-341, Bendamustine HCl, Treanda, Proteasome inhibitor |
| Sponsor | University of Arkansas |
| Target | 26S proteasome non-ATPase regulatory subunit 1, PH and SEC7 domain-containing protein 1, Cathepsin G |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Mantle cell lymphoma
- Multiple myeloma
- Systemic AL amyloidosis
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Peripheral neuropathy
- Thrombocytopenia
- Constipation
- Vomiting
- Anorexia
- Neutropenia
- Leukopenia
- Lymphopenia
- Rash
Serious adverse events
- Diarrhea
- Dehydration
- Herpes zoster
- Pyrexia
- Nausea
- Vomiting
- Dyspnea
- Thrombocytopenia
Key clinical trials
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma (PHASE2)
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (PHASE1)
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (PHASE1)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
- Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Velcade CI brief — competitive landscape report
- Velcade updates RSS · CI watch RSS
- University of Arkansas portfolio CI
Frequently asked questions about Velcade
What is Velcade?
What is Velcade used for?
Who makes Velcade?
Is Velcade also known as anything else?
What development phase is Velcade in?
What are the side effects of Velcade?
What does Velcade target?
Related
- Target: All drugs targeting 26S proteasome non-ATPase regulatory subunit 1, PH and SEC7 domain-containing protein 1, Cathepsin G
- Manufacturer: University of Arkansas — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Mantle cell lymphoma
- Indication: Drugs for Multiple myeloma
- Indication: Drugs for Systemic AL amyloidosis
- Also known as: Bortezomib, PS-341, Bendamustine HCl, Treanda, Proteasome inhibitor
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing